Literature DB >> 32614722

Risk Factors, Molecular Epidemiology, and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection for Hospital-Acquired Pneumonia: A Matched Case-Control Study in Eastern China During 2015-2017.

Yan Zuo1, Dongmei Zhao2, Guobin Song1, Jiabin Li2, Yuanhong Xu1, Zhongxin Wang1.   

Abstract

This study was conducted to acknowledge microbiological and clinical characteristics of hospital-acquired pneumonia (HAP) caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). A retrospective, 1:1 matched (age, gender, specimen source, and ward) case-control study was conducted during 2015-2017 in a tertiary teaching hospital in Anhui, China. Multivariate logistic regression analysis demonstrated that prior central venous catheter use, sputum suction, continuous renal replacement therapy, and exposure to fluroquinolones were independent risk factors for the morbidity of CRKP infection for HAP. Treatment failure for infection was an independent risk factor for crude in-hospital mortality, while the use of fluroquinolones may improve the effective treatment for infection (p = 0.040). Among 74 CRKP strains, 85.1% of them were positive for the production of KPC-2, and one of them was detected for co-harboring blaKPC-2 and blaIMP-38-like. Separately, sequence type (ST) 11 (81.1%) was the predominant ST in this study, and ST11 CRKP isolates were related with higher detection rate of blaKPC-2 and lower resistance rate to trimethoprim/sulfamethoxazole when compared with non-ST11 ones. Moreover, resistance to carbapenem was associated with higher mortality (35.1%) and hospitalization costs for HAP patients with K. pneumoniae infection. Invasive procedures may increase the morbidity of CRKP infection for HAP. Prior exposure to fluroquinolones is associated with the development of resistance, but as a targeted treatment it may be effective.

Entities:  

Keywords:  carbapenem-resistant Klebsiella pneumoniae; hospital-acquired pneumonia; molecular epidemiology; outcomes; risk factors

Year:  2020        PMID: 32614722     DOI: 10.1089/mdr.2020.0162

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  4 in total

1.  Predictors of Occurrence and 30-Day Mortality for Co-Infection of Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Dongmei Lv; Yan Zuo; Yuerong Wang; Zhongxin Wang; Yuanhong Xu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-20       Impact factor: 6.073

2.  Risk Factors and Prognosis of Carbapenem-Resistant Klebsiella pneumoniae Infections in Respiratory Intensive Care Unit: A Retrospective Study.

Authors:  Huan Zhang; Jin Wang; Weiying Zhou; Ming Yang; Rui Wang; Xin Yan; Yun Cai
Journal:  Infect Drug Resist       Date:  2021-08-19       Impact factor: 4.003

3.  Clinical Outcomes and Microbiological Characteristics of Sequence Type 11 Klebsiella pneumoniae Infection.

Authors:  Ping Yang; Zhenchao Wu; Chao Liu; Jiajia Zheng; Nan Wu; Zhangli Wu; Juan Yi; Ming Lu; Ning Shen
Journal:  Front Med (Lausanne)       Date:  2022-05-16

4.  Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis.

Authors:  Ruyin Zhou; Xiangming Fang; Jinjin Zhang; Xiaodong Zheng; Shuangyue Shangguan; Shibo Chen; Yingbo Shen; Zhihai Liu; Juan Li; Rong Zhang; Jianzhong Shen; Timothy R Walsh; Yang Wang
Journal:  BMJ Open       Date:  2021-12-14       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.